Oncolytic virus OH2 induces PD-L1 upregulation via NF-κB signaling and synergizes with anti-PD-L1 therapy in prostate cancer through a targeted extracellular vesicle delivery system - PubMed
3 months ago
- #Immunotherapy
- #Prostate Cancer
- #Oncolytic Virus
- Oncolytic virus OH2 shows efficacy in killing prostate cancer cells but upregulates PD-L1 via NF-κB signaling, leading to adaptive immune resistance.
- A novel targeted delivery system, OH2@RRA-AP-EVs, was developed to enhance tumor targeting and enable ROS-triggered PD-L1 blockade.
- Intravenous administration of OH2@RRA-AP-EVs resulted in 70% greater tumor growth inhibition compared to free OH2 and enhanced CD8+ T cell infiltration.
- The study provides a mechanism for OH2-induced PD-L1 expression and introduces a versatile delivery platform for viro-immunotherapy in prostate cancer.